u/peak_area_pete

The endpoint vocabulary, because you cannot read this literature without it.

Resolution of steatohepatitis without worsening of fibrosis and improvement in fibrosis without worsening of steatohepatitis are the two standard composite endpoints, both scored on biopsy by pathologists against a defined system. Liver fat fraction is an imaging surrogate that correlates imperfectly with histology.

A trial can move the surrogate substantially and the histological endpoint modestly. Both results are real; they answer different questions. Anybody quoting a response rate here should say which endpoint it refers to, and most summaries do not.

The four columns that survive, after several people here have tried and abandoned much more elaborate systems.

Date. Dose. One number measured under consistent conditions. A short note when anything unusual happened. That is it. Anything more and you will stop, and a log you stop keeping is worth less than a crude one you maintain.

Add a waist measurement monthly if you can be bothered, and a sleep column if you want the one variable that explains the most confusing weeks. Everything else can be reconstructed from those, and nothing can be reconstructed from a log you abandoned in week nine.

retrospective logs drift, contemporaneous ones do not

Correcting my own log post above: I had the dose recorded wrongly for one fortnight and have amended it.

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.

How long have you been logging?

two labs, two gradients, two honest answers

the diagnosis code on the claim is doing more work than anything you write

Missing entries recorded as blanks preserve the shape of the series. Dropping them silently makes the remaining points look more regular than they were.

The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why. That is a description of the trials rather than a suggestion for anybody.

Agreed on the plan-year point.

Adding the underused one — external review. Independent, binding where it applies, and hardly anybody gets that far.

Same method at both labs, or two different gradients?

A peer-to-peer conversation puts the prescribing clinician in front of a reviewing clinician. It bypasses the correspondence cycle entirely and is often the fastest available route.

Retitled: the original claimed a comparison the post does not actually make.

Trace posted without axis labels — asked for a relabelled version rather than removing it.

Trace posted without axis labels — asked for a relabelled version rather than removing it.

you cannot report to two decimals off that baseline

Left up. The integration disagreement in this thread is the most useful thing on the board this week.

Disagree with the tone strategy. Anger has never moved a determination; matching the criterion has.

Attribution requires that one thing change at a time. A log with dose, training and intake all moving in the same fortnight cannot assign anything to any of them.

Trace posted without axis labels — asked for a relabelled version rather than removing it.

Reconstructed six weeks from memory once and later found receipts that contradicted my own log. Never again.

Same.

Adding the column everyone adds late — sleep. Start with it.

Push back: a longer run is not automatically better resolution. You are trading peak width for time and the ratio is what matters.

Area percent is the integrated area of your peak over the total integrated area at one wavelength on one gradient. Change any of those and the number changes without the sample changing.

Agreed.

Disagreeing with this bit: that spread is ordinary inter-lab variance, not a disagreement about the material.

Correction: that is a tailing factor, not a plate count. Different diagnostics for different problems.

Method questions stay here; supplier claims go to c/vendorvetting with a document attached.

What did system suitability look like on that sequence?

I would not blame the sample yet. Everything you have described is consistent with the column rather than the vial.

Choose a format you will still be able to open in two years. Plain text or a spreadsheet you export beats an application that may not exist.

Method questions stay here; supplier claims go to c/vendorvetting with a document attached.

What has been documented as tried, and for how long?

Asked for the policy bulletin by number and wrote the appeal against its criteria line by line. Approved on the second level after a flat first-level denial.

Choose a format you will still be able to open in two years. Plain text or a spreadsheet you export beats an application that may not exist.

Mass spectrometry answers identity. UV purity answers relative quantity under the run conditions. A document with one and not the other is answering half the question, and the half it answers should be stated.

integration decisions move the number more than the sample does

Step therapy requires documented trial of preferred alternatives.

Disagreeing with this line: the deadline runs from the letter date and treating it otherwise is expensive.

Logged the missed weeks as blanks rather than skipping them. The gaps turned out to be the informative part.